Registration Now Open for the 2025 MDA Clinical & Scientific Conference Featuring the Latest Innovations in Neuromuscular Disease Research and Care with Global Leaders, March 16-19 in Dallas, TX
2024年7月31日 - 12:53AM
The Muscular Dystrophy Association (MDA), convener of the largest
global gathering of the neuromuscular disease community, announced
today that registration is now open for the 2025 MDA Clinical &
Scientific Conference being held March 16-19, 2025, at the Hilton
Anatole in Dallas, Texas. This milestone four-day conference will
bring together renowned researchers, clinicians, academicians,
advocates, and industry leaders to explore the latest advances in
the field of neuromuscular disease. Early bird registration ends on
December 31, 2024. To register, click here. The 2025 MDA
Clinical & Scientific Conference will feature presentations
from global leaders on all aspects of pre-clinical, translational,
and clinical research and care across neuromuscular diseases
including amyotrophic lateral sclerosis (ALS), Duchenne muscular
dystrophy (DMD), spinal muscular atrophy (SMA), limb-girdle
muscular dystrophy (LGMD), myasthenia gravis (MG),
Charcot-Marie-Tooth disease (CMT), and many more. Session tracks
will highlight topics including:
- Strategies for
regenerating muscle and nerve tissue
- New insights into
disease mechanisms
- Clinical experience
in gene therapy
- Access and
reimbursement
- Clinical trial
readouts
"Since 1950 when we began the work to establish the field of
neuromuscular disease, we have been funding and propelling forward
research that has led to the extraordinary breakthroughs we see
today in treatments and care. The 2025 MDA Clinical and Scientific
Conference is globally renowned for convening the foremost
neuromuscular disease scientists, clinicians, and advocacy
organizations of the day to share cutting-edge research, explore
innovative treatments, and address access to new therapies," said
Donald S. Wood, Ph.D., President & CEO, MDA. "This
conference is a catalyst for new pathways of scientific exploration
at the medical frontiers of neuromuscular disease. Our
history-making success in creating more-and-more FDA approved
treatments is changing the trajectory of diseases like Duchenne
muscular dystrophy, spinal muscular atrophy, ALS, and related
disorders.”
Last year’s conference included 1,492 in-person and 567 virtual
attendees from over 30 countries, making it the largest worldwide
gathering of the neuromuscular disease community.
"The 2025 MDA Clinical and Scientific Conference will explore
neuromuscular research and care with particular attention to some
of the changes the field is undergoing in response to the approval
of new therapies,” said Sharon Hesterlee, Ph.D., Chief Research
Officer, MDA. “In particular, as newly approved drugs help slow
or stop progression of neuromuscular diseases, we need to better
understand how to regenerate muscle and nerve tissue that has
already been lost to the disease process.
“The MDA Clinical and Scientific Conference is an opportunity to
stay up to date on the most impactful science and the latest in
clinical practice knowledge for the benefit of the neuromuscular
patient community,” said Barry Byrne, M.D., Ph.D., Chief Medical
Advisor, MDA and Associate Chair of Pediatrics and Director of the
Powell Gene Therapy Center at the University of Florida. “All
of us at the Muscular Dystrophy Association are looking forward to
seeing everyone in Dallas in March.”
“MDA’s Conference will once again serve as the primary gathering
and collaborative space for the neuromuscular patient advocacy
community,” said Paul Melmeyer, Executive Vice President, Public
Policy and Advocacy, MDA. “We will build upon the progress of
previous Conferences where over 30 advocacy organizations have
gathered to collaborate and align on legislative priorities for the
community including access to care, speeding the therapeutic
development process, and breaking down barriers in front of people
living with disabilities.”
Members of the neuromuscular disease community registered with
MDA are welcome to participate in the virtual conference at no-cost
or may register to attend in-person at the patient/caregiver rate
until allotted spaces are filled.
2025 MDA Clinical & Scientific Conference Social Media
Toolkit for registrants, panelists, supporters/sponsors, and
advocacy organizations, is available here. MDA will be sharing
updates and information on its social media channels using
#MDAconference.
Abstract Submission GuidelinesThe abstract submission
portal is now open. All abstracts automatically qualify for poster
presentations. For those submitting an abstract who would like to
be considered for oral presentations at the 2025 MDA Clinical &
Scientific Conference, highest priority will be given to those who
submit abstracts on or before November 15, 2024. The final
deadline for oral presentation consideration is December 31, 2024.
All abstracts automatically qualify for the poster session. Should
there be any questions regarding this policy, please contact
mdaconference@mdausa.org.
About Muscular Dystrophy AssociationMuscular Dystrophy
Association (MDA) is the #1 voluntary health organization in
the United States for people living with muscular dystrophy, ALS,
and related neuromuscular diseases. For over 70 years, MDA has led
the way in accelerating research, advancing care, and advocating
for the support of our families. MDA's mission is to empower the
people we serve to live longer, more independent lives. To learn
more visit mda.org and follow MDA
on Instagram, Facebook, X, Threads, TikTok, LinkedIn,
and YouTube.
- 2025 MDA Clinical & Scientific Conference
Mary Fiance, Vice President, Strategic Communications
Muscular Dystrophy Association
press@mdausa.org